Related Experiment Video
Updated: Jan 6, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care
Suying Li1, Uche Mordi2, Mary J Christoph2
1Chronic Disease Research Group, 701 Park Ave., Suite S2.100, Minneapolis, MN, 55415, USA. suying.li@cdrg.org.
Introduction:
Adherence to antiretroviral therapy (ART) is crucial for people with HIV (PWH) to maintain health. The Medicare program insures a substantial proportion of PWH in the United States; however, few studies have evaluated ART treatment patterns in this population. This study described treatment persistence and switch patterns among Medicare-insured PWH with low ART adherence or significant treatment gaps prior to re-initiating ART.
Methods:
A retrospective cohort study was conducted using data from Medicare Fee-For-Service and Medicare Advantage from January 2017 to December 2022. PWH aged ≥ 18 years with documented treatment experience receiving an index ART regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/lamivudine (DTG/3TC), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC), or multi-tablet regimens (MTRs; dolutegravir + emtricitabine/tenofovir alafenamide [DTG + F/TAF] or dolutegravir + emtricitabine/tenofovir disoproxil fumarate [DTG + F/TDF]) were included. Study groups of interest included PWH with low adherence (defined as a proportion of days covered [PDC] < 85%) and PWH who had initiated index ART after a ≥ 90-day gap. Treatment nonpersistence (discontinuation or switch) and switch outcomes were evaluated using Kaplan-Meier curves and Cox proportional hazards models.
Results:
Of 30,205 treatment-experienced PWH, 6140 had low adherence on the index regimen and 7227 had significant treatment gaps prior to re-initiating ART. In both groups, risk of treatment nonpersistence was significantly lower for PWH indexed on B/F/TAF versus DTG/ABC/3TC and MTRs but similar for DTG/3TC. Risk of treatment switch was lower for those indexed on B/F/TAF versus all other ART regimens evaluated (P < 0.01).
Conclusions:
Among Medicare-insured PWH with low adherence or significant gaps in care, those receiving B/F/TAF had a lower risk of switch compared with other ART regimens. Optimizing ART selection to improve persistence and reduce treatment switching remains an important consideration.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Introduction To Health Care Delivery System
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

